The Derm Directory

Retin-A-Micro

Click here for a list of legend definitions

Clinical Pearls & Key Features:

The 12-week P.U.M.P. Study (Patients Using Micro Properly) of RETIN -A MICRO Pump (N=544) proves:

  • Reduced acne severity with minimal irritation—reported incidence of erythema was 1.8%, dry skin 3.3%, and burning 0.2% for RETIN -A MICRO 0.04% and 0.1% combined.
  • Greater satisfaction—patients were 3x more satisfied at the conclusion of the P.U.M.P. Study.
  • Improved compliance—approximately 95% of patients reported high compliance.

      • Commentary:

      The RETIN -A MICRO Pump delivers the most prescribed retinoid of all time—tretinoin—with a high level of control over irritation potential. The RETIN -A MICRO Pump promotes proper use and helps prevent overuse. State-of-the-art microsphere technology disperses tretinoin penetration into the skin over time. As a result, RETIN -A MICRO Pump significantly clears noninflammatory and inflammatory lesions, with minimal irritation to deliver high satisfaction and high reported compliance.

Drugs » Acne: Topical

← PREVIOUS NEXT →

Retin-A Micro® (tretinoin gel)

Retin-A Micro<sup>®</sup>

How Supplied:

0.04% and 0.1% gel, 50 g pump 0.04% and 0.1% gel, 20 g and 45 g tube

Indications and Usage:

RETIN -A MICRO (tretinoin gel) microsphere, 0.04% and 0.1%, are indicated for topical application in the treatment of acne vulgaris.

Prescribing Instructions:

Prescribing Information Instructions [PDF]

Side Effects and Contraindications:

In pivotal trials, RETIN -A MICRO 0.04% and 0.1% have proven to be well-tolerated. The most common adverse reactions were limited to mild to moderate cutaneous irritation.1 1.3% of patients using RETIN -A MICRO 0.04% and 6% of patients using RETIN -A MICRO 0.1% discontinued due to irritation. Contraindications: This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components. It should be discontinued if hypersensitivity to any of its ingredients is noted.

Company:

Ortho Dermatologics
310-642-1150
www.retinamicro.com

References:

1. RETIN -A MICR O 0.04%/0.1% [prescribing information]. Los Angeles, Calif: OrthoNeutrogena; May 2006.
2. Data on file, OrthoNeutrogena.
3. IMS Health, National Prescription Audit, September 2008.
4. Embil K, Nacht S. The Microsponge¨ Delivery System (MDS ): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575-588.
5. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1, suppl):S1-S37.

Retin-A Micro<sup>®</sup>

← PREVIOUS NEXT →